1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Lipitor® (Atorvastatin Calcium) Tablets

Trade Name: Aspavor, Atorvastatin, Atorvastatin Almus, Cardyl, Citalor, Eturion, Lipitor, Liprimar, Sortis, Tahor, Torvast, Xarator, Zarator, Texzor, Atorvastatina, Orbeos, Totalip

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Lipid regulating agent.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification: Not classified as hazardous

EU Classification:
EU Indication of danger: Not classified

Label Elements

Other Hazards: No data available

Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
</table>
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin calcium</td>
<td>134523-03-8</td>
<td>Not Listed</td>
<td>R52/53</td>
<td>Aquatic Acute 3; H402; Aquatic Chronic 3; H412</td>
<td>7.0</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>471-34-1</td>
<td>207-439-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Simethicone emulsion</td>
<td>67762-90-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>74811-65-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>9004-64-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry white</td>
<td>NOT ASSIGNED</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>9005-65-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove contaminated clothing and shoes. Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Atorvastatin calcium
Pfizer OEL TWA-8 Hr: 50 µg/m³

Calcium carbonate
Australia TWA: 10 mg/m³
Bulgaria OEL - TWA: 10.0 mg/m³
France OEL - TWA: 10 mg/m³
Latvia OEL - TWA: 6 mg/m³
Poland OEL - TWA: 10 mg/m³
Portugal OEL - TWA: 10 mg/m³
Vietnam OEL - TWAs: 10 mg/m³

Microcrystalline cellulose
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Exposure Controls**

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State:** Tablet

**Odor:** No data available.

**Molecular Formula:** Mixture

**Solvent Solubility:** No data available

**Water Solubility:** No data available

**pH:** No data available.

**Melting/Freezing Point (°C):** No data available

**Boiling Point (°C):** No data available.

**Partition Coefficient:** Method, pH, Endpoint, Value

**Microcrystalline cellulose**

**Lactose NF, monohydrate**
9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Calcium carbonate
No data available

Opadry white
No data available

Hydroxypropyl cellulose
No data available

Simethicone emulsion
No data available

Magnesium stearate
No data available

Polysorbate 80
No data available

Atorvastatin calcium
No data available

Crocarmellose sodium
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause eye irritation (based on components).

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver.
11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: Adverse effects associated with therapeutic use of atorvastatin include constipation, flatulence, upset stomach, and abdominal pain. Clinical use of this drug has caused changes in liver function, muscle pain, weakness.

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose
- Rat Oral LD50 > 5000 mg/kg
- Rabbit Dermal LD50 > 2000 mg/kg

Calcium carbonate
- Rat Oral LD50 6450 mg/kg

Magnesium stearate
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

Polysorbate 80
- Rat Oral LD50 25 g/kg

Atorvastatin calcium
- Rat/Mouse Oral LD50 > 5000 mg/kg
- Rabbit Dermal LD50 > 2000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose
- Skin Irritation Rabbit Non-irritating
- Eye Irritation Rabbit Non-irritating

Atorvastatin calcium
- Skin Sensitization - Beuhler Guinea Pig Negative
- Skin Irritation Rabbit Non-irritating
- Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Atorvastatin calcium
- 104 Week(s) Dog Oral 10 mg/kg/day LOAEL Liver
- 13 Week(s) Mouse Oral 100 mg/kg/day LOAEL Liver
- 52 Week(s) Rat Oral 5 mg/kg/day NOAEL Liver
- 13 Week(s) Rat Oral 5 (male); 20 (female) mg/kg/day NOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Atorvastatin calcium
- Reproductive & Fertility Rat Oral 20 mg/kg/day NOAEL Negative
- Fertility and Embryonic Development Rat Oral 100 mg/kg/day NOAEL Negative
- Embryo / Fetal Development Rat Oral 100 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity
11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**Atorvastatin calcium**

*In Vitro* Bacterial Mutagenicity (Ames)  *Salmonella*, *E. coli*  Negative  
*In Vivo* Micronucleus  Mouse Bone Marrow  Negative  
Mutagenicity  No evidence of mutagenic or clastogenic activity in in vitro or in vivo tests.

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Atorvastatin calcium**

104 Week(s)  Mouse  Oral  200 mg/kg/day  NOAEL  Not carcinogenic  
104 Week(s)  Rat  Oral  100 mg/kg/day  NOAEL  Not carcinogenic

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:  In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil. Not readily biodegradable. May have harmful effects on the aquatic environment. May persist in the aquatic environment. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

**Atorvastatin calcium**

*Daphnia magna* (Water Flea)  EC50  48 Hours  200 mg/L  
*Oncorhyncus mykiss* (Rainbow Trout)  OECD  LC50  96 Hours  > 92 mg/L  
*Pseudokirchneriella subcapitata* (Green Alga)  OECD  EbC50  72 Hours  75 mg/L  
*Daphnia magna* (Water Flea)  OECD  NOEC  21 Days  0.14 mg/L  
*Pimephales promelas* (Fathead Minnow)  OECD  NOEC  32 Days  0.45 mg/L  
Aquatic Toxicity Comments:  The (21) day (NOEC) study above is a reproductive/survival study. The 32 day study above is an Early Life-Stage Toxicity test. A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

**Atorvastatin calcium**

*Aspergillus niger* (Fungus)  MIC  > 1000 mg/L  
*Trichoderma viride* (Fungus)  MIC  > 1000 mg/L  
*Clostridium perfringens* (Bacterium)  MIC  100 mg/L  
Activated sludge  OECD  EC50  > 1000 mg/L

Persistence and Degradability:  No data available

**Atorvastatin calcium**

TAD  Soil (various)  Ultimate (CO2 Evolution)  <10% After  28 Day(s)  Not Ready  
OECD  Activated sludge  Ultimate (CO2 Evolution)  <10% After  28 Day(s)  Not Ready
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

**Canada - WHMIS: Classifications**

WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

**Simethicone emulsion**

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

**Atorvastatin calcium**

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
### 15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>EU EINECS/ELINCS List</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>REACH - Annex XVII - Restrictions on Certain Dangerous Substances:</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium carbonate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>Use restricted. See item 9[f], powder</td>
<td>207-439-9</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Opadry white</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>232-674-9</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>209-150-3</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
</tbody>
</table>
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>California Proposition 65</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects

R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 12-Jun-2014

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet